ClinicalTrials.gg
CompletedNCT04847817AIDCOUpdated Jul 19, 2022

Important Data on COVID-19 Profile in Africa

An observational study in Coronavirus Infection and Africa, sponsored by Centre de Recherche Médicale de Lambaréné. Completed at 2 sites in Gabon. Per ClinicalTrials.gov, last updated 2022-07-19.

Primary conditionCOVID-19Registry: Coronavirus InfectionsReclassifiedWhy we changed it
Registry
Coronavirus Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
COVID-19
Why
  1. The study's title name COVID-19, a narrower term within Coronavirus Infections.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Centre de Recherche Médicale de Lambaréné · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
574
Sex
All
01

Study summary

The purpose of this study is to Understand the natural history of Coronavirus 2019 (COVID-19) infection to better define the period of infectiousness and transmissibility and to establish biobanks of COVID-19 blood and mucosal samples.

Read the detailed description

In this study ,the participants will be enrolled sequentially in the COVID-19 care referral centers. The infected hospitalized patient will be identified by the physicians in hospital. After the patient has given his/her informed consent the permission will be sought from him to approach his household contacts. The household contacts will be screened, and included in the study.

Patients hospitalized and positive for COVID-19 by PCR and their household contacts of all ages and gender (40% minimum of female), will be enrolled upon receipt of written informed consent.

02

Conditions studied

  • Coronavirus Infection
  • Africa

Browse trials for

Keywords

  • Coronavirus infection
  • SARS-CoV
  • COVID-19
  • Transmission
  • Africa
03

In context

COVID-19 Reclassified

7,990 studies on the registry are indexed under COVID-19; 466 are open to participants now.

This study's enrollment of 574 is above the median of 268 across 3,208 observational studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

Centre de Recherche Médicale de Lambaréné is the lead sponsor of 17 studies on the registry; 3 are open to participants now.

Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Sampling method
Probability sample

Study population

The study population will consist of volunteer COVID-19 patients hospitalized in referral center for COVID-19 care as well as the household contacts of these hospitalized COVID-19 patients in Gabon, Senegal and Ethiopia.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Molecular (PCR) confirmed COVID-19 patients hospitalized in referral centers,
  • Household contacts of hospitalized COVID-19 patient,
  • Provided signed .

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
574 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Index cases

    Patients infected by SARS-Cov2 Polymerase Chain Reaction (PCR) and hospitalized in a referral center for COVID-19 .

  • Households cases

    Household contacts of SARS-Cov2 hospitalized COVID-19 patients.

06

What researchers measure

Primary outcomes

  1. clinical and biological parameters of COVID-19

    Infection and disease progression - Pattern of virus transmission

    Time frame: 14 days

  2. SARS-CoV-2 transmissibility

    proportion of household contact who will become positive for SARS-COV2 using PCR

    Time frame: 14 days

07

Study locations

2 sites
  • Centre de Recherches Médicales de Lammbaréné
    Lambaréné, Moyen- Ogooué 1437, Gabon
  • Centre de Recherches Médicales de Lambréné
    Lambaréne, Gabon
08

References and documents

Individual participant data

Plan to share: Yes — Results from our COVID-19 AFRICA, AIDCO, project will be published in peer reviewed journals, seeking rapid and open access publication. This will be done as fast and widely as possible. Results will also be submitted and presented in any national, regional and international scientific meetings and congresses dedicated to COVID-19 online or face to face if, permitted. Before submission for publication or presentation, the review process outlined in the Consortium Agreement and agreed upon by all partners will be followed and care will be taken with respect to intellectual property protection.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: 2 years

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 19, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04847817
Lead sponsor
Centre de Recherche Médicale de Lambaréné
Collaborators
European and Developing Countries Clinical Trials Partnership (EDCTP), Leiden University Medical Center, Institut de recherche en santé de surveillance épidémiologique et de formation, Université des Sciences de la Santé, Armauer Hansen Research Institute, Ethiopia, Universität Tübingen
Responsible party
Sponsor
First posted
Apr 19, 2021
Start date
Aug 1, 2020
Primary completion
Dec 31, 2021
Completion
Mar 1, 2022
Last update
Jul 19, 2022

Study contacts

Ayôla Akim ADEGNIKA
principal investigator · Centre de Recherches Médicales de Lambaréné
Marielle BOUYOU-AKOTET
principal investigator · Université des Sciences de Santé
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion